Abenza announces investment in bioconjugation and ADC capabilities
Betsy Goodfellow | March 28, 2024 | News story | Business Services | ADC, Abenza, Pharmacy, bioconjugation, investment
Abenza has announced a major investment in bioconjugation and antibody drug conjugate (ADC) capabilities in response to an increasing industry demand.
The company intends to expand its bioconjugate development and cGMP manufacturing site in Bristol, Pennsylvania, US, with a $5m investment. It is hoped that the company can spend the investment on expanding its laboratory space, acquiring new equipment and upgrading its facilities, while building on the existing bioconjugation capabilities at the site.
Ian Glassford, vice president and head of the Bristol site, commented: “The integration of the Waters Arc Premier and ACQUITY Premier Chromatography systems alongside the Sartorius Hipersep Flowdrive represents a quantum leap in our operational capabilities. Combined with our comprehensive site renovations, these advancements enhance our capabilities to better support customer programmes and affirms our dedication to creating a supportive workplace for our employees.”
Matt Stober, CEO of Abzena, added: “The strategic investment into our Bristol site demonstrates our continued commitment to deliver high-quality programmes for our customers that offer them the best chances of downstream success. We have seen a significant increase in bioconjugate and antibody-drug conjugate (ADC) programmes in today’s development pipelines, and as an industry leader with over 20 years of experience in this space, we will continue to invest in our facilities across all of our sites to offer cost and time efficiencies so that these programmes can reach patients faster.”
Betsy Goodfellow
Related Content
Apiary invests in life sciences SEO pioneer PIO to support global expansion
Private equity firm Apiary Capital has invested in performance-io (PIO), a specialist life sciences performance …
Amferia closes €1,2 million investment to combat resistant bacterial infections
Swedish medtech company Amferia announces the successful completion of its latest investment round, boosting its …
Novo Holdings Invests in Oxford Nanopore Technologies
leading life science investor Novo Holdings, announced a £50m investment in Oxford Nanopore Technologies. Oxford …
